Last reviewed · How we verify
KIACTA (eprodisate disodium)
Eprodisate disodium inhibits glycosaminoglycan (GAG) synthesis and accumulation by blocking the formation of pathogenic protein-GAG complexes in amyloid-related diseases.
Eprodisate disodium inhibits glycosaminoglycan (GAG) synthesis and accumulation by blocking the formation of pathogenic protein-GAG complexes in amyloid-related diseases. Used for Transthyretin (TTR) amyloidosis.
At a glance
| Generic name | KIACTA (eprodisate disodium) |
|---|---|
| Sponsor | C.T. Development America, Inc. |
| Drug class | Amyloid inhibitor |
| Target | Glycosaminoglycan (GAG) synthesis and amyloid-GAG interaction |
| Modality | Small molecule |
| Therapeutic area | Rare Genetic Diseases / Amyloidosis |
| Phase | Phase 3 |
Mechanism of action
Eprodisate is a small molecule that interferes with the interaction between amyloid proteins and glycosaminoglycans, which are thought to play a key role in amyloid fibril formation and tissue deposition. By reducing GAG-mediated amyloid stabilization and accumulation, the drug aims to slow or halt disease progression in amyloidosis. This mechanism targets the underlying pathophysiology of amyloid diseases rather than simply managing symptoms.
Approved indications
- Transthyretin (TTR) amyloidosis
Common side effects
- Gastrointestinal disturbances
- Injection site reactions
- Nausea
Key clinical trials
- Efficacy and Safety Study of KIACTA in Preventing Renal Function Decline in AA Amyloidosis (PHASE3)
- A Phase IIa Proof-of-concept Study of NC-503 in Patients With Type II Diabetes (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- KIACTA (eprodisate disodium) CI brief — competitive landscape report
- KIACTA (eprodisate disodium) updates RSS · CI watch RSS
- C.T. Development America, Inc. portfolio CI